



# MARKET RELEASE

8 December 2017

## **Zelda Therapeutics Limited**

### TRADING HALT

The securities of Zelda Therapeutics Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Tuesday 12 December 2017 or when the announcement is released to the market.

Security Code: ZLD

Dawn James

**Adviser, Listings Compliance (Perth)**



8 December 2017

Australian Securities Exchange Limited  
40 Central Park  
152 – 158 St Georges Terrace  
PERTH WA 6000

Attention: Isabelle Andrews  
By email only: [isabelle.andrews@asx.com.au](mailto:isabelle.andrews@asx.com.au)

Dear Sir

**TRADING HALT REQUEST**

In accordance with ASX Listing Rule 17.1, Zelda Therapeutics Limited (ASX: ZLD) requests the granting of a trading halt in ZLD's ordinary securities listed on the ASX pending an announcement regarding a material and significant partnership with a US-based research institution.

It is requested that the trading halt apply immediately until the earlier of ZLD making an announcement concerning this partnership, or the opening of trading on Tuesday, 12 December 2017.

ZLD confirms that it is not aware of any reason why a trading halt should not be granted or any other information necessary to inform the market about the trading halt.

Yours sincerely

Tim Slate  
**Company Secretary**

**Corporate**

Mr Harry Karelis  
Executive Chairman  
Mobile: +61 413 056 328  
[hkarelis@zeldatherapeutics.com](mailto:hkarelis@zeldatherapeutics.com)

**Investors**

Dr Stewart Washer  
Executive Director  
Mobile: +61 418 288 212  
[swasher@zeldatherapeutics.com](mailto:swasher@zeldatherapeutics.com)



**About Zelda Therapeutics ([www.zeldatherapeutics.com](http://www.zeldatherapeutics.com))**

Zelda Therapeutics ("Zelda") is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising:

- A human clinical trial programme focused on insomnia, autism and eczema with activities in Australia and Chile.
- A pre-clinical research programme examining the effect of cannabinoids in breast, brain and pancreatic cancer. It has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer.